Adenosine Deaminase-Severe Combined Immunodeficiency Market Forecast: Breaking Down The Numbers Behind Future Expansion
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Adenosine Deaminase-Severe Combined Immunodeficiency Market Poised To Hit $8.11 Billion By 2030 With A 6.4% CAGR
The adenosine deaminase-severe combined immunodeficiency market size has demonstrated robust growth over recent years. It is projected to increase from $5.94 billion in 2025 to $6.33 billion in 2026, at a compound annual growth rate (CAGR) of 6.6%. The expansion observed during the historic period can be linked to factors such as limited awareness of ada-scid, low availability of gene therapy solutions, reliance on supportive care treatments, lack of specialized treatment centers, and a high prevalence of treatment delays.
The market for adenosine deaminase-severe combined immunodeficiency is projected to experience robust expansion over the coming years. This market is forecast to reach $8.11 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.4%. This anticipated growth during the forecast period is primarily driven by progress in autologous stem cell therapies, improved accessibility of enzyme replacement therapy, the proliferation of specialized hospitals and clinics, an increase in pediatric diagnosis rates, and enhanced healthcare funding specifically for rare genetic disorders. Key trends emerging over the forecast horizon encompass the growing adoption of enzyme replacement therapies, the advancements in and improved access to gene therapy solutions, an increase in stem cell transplantation procedures, the broadening of pediatric treatment programs for ADA-SCID, and a heightened emphasis on supportive care and consistent patient monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Adenosine Deaminase-Severe Combined Immunodeficiency Market Growth Drivers: What’s Behind The Acceleration?
The expanding occurrence of genetic disorders is projected to stimulate the growth of the adenosine deaminase-severe combined immunodeficiency market moving forward. Genetic disorders are medical conditions resulting from anomalies or changes in an individual’s DNA, whether passed down or developing spontaneously. The growing incidence of genetic disorders is influenced by elements such as enhanced diagnostic technologies, heightened public awareness, an increase in parental age, environmental factors, and population expansion. This rise in genetic disorders, particularly for conditions like adenosine deaminase-severe combined immunodeficiency (ADA-SCID), necessitates greater demand for sophisticated diagnostic methods and targeted therapies. As an illustration, in October 2024, the Cystic Fibrosis Trust, a national charity based in the UK, stated that 11,148 people were living with cystic fibrosis (CF) in the UK in 2022, a figure that climbed to 11,318 by 2023. Thus, the increasing prevalence of genetic disorders is fostering the expansion of the adenosine deaminase-severe combined immunodeficiency market.
Adenosine Deaminase-Severe Combined Immunodeficiency Market Segment Trends And Revenue Contributors
The adenosine deaminase-severe combined immunodeficiency market covered in this report is segmented –
1) By Treatment Type: Enzyme Replacement Therapy (ERT), Gene Therapy, Stem Cell Transplantation, Supportive Care Treatments
2) By Route of Administration: Intravenous, Subcutaneous
3) By End-User: Hospitals, Specialty Clinics
Subsegments:
1) By Enzyme Replacement Therapy (ERT): Pegylated Adenosine Deaminase, Non-Pegylated Adenosine Deaminase
2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy, Viral Vector-Mediated Gene Therapy
3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant, Umbilical Cord Blood Transplant
4) By Supportive Care Treatments: Antimicrobial Therapy, Immune System Support
Adenosine Deaminase-Severe Combined Immunodeficiency Market Trends: What’s Defining The Industry’s Next Phase?
Leading organizations in the adenosine deaminase-severe combined immunodeficiency treatment market are prioritizing the development of advanced solutions, such as manufacturing gene therapies internally. This strategy aims to improve patient access, reduce treatment costs, and ensure consistent supply. In-house gene therapy production refers to the method of creating autologous hematopoietic stem cells, genetically altered with a healthy ADA gene, directly within an organization’s own facility, thereby decreasing reliance on commercial manufacturers. For instance, in February 2025, the Fondazione Telethon, an Italy-based nonprofit biomedical research organization, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etuvetidigene autotemcel. This gene therapy was originally developed for ADA-SCID and is now also targeting Wiskott-Aldrich Syndrome. The therapy involves a single administration of autologous CD34+ stem and progenitor cells transduced with a lentiviral vector encoding the functional gene, which has shown promising safety and efficacy results in treated patients.
Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A., Orchard Therapeutics PLC, Rocket Pharmaceuticals, Novartis AG, Bluebird Bio, Spark Therapeutics, Leadiant Biosciences, Sigma-Tau Pharmaceuticals, Astellas Pharma, Takeda Pharmaceutical Company, Pfizer Inc, Sanofi, Bristol-Myers Squibb, Roche Holding AG, Johnson & Johnson, AbbVie Inc, Gilead Sciences, CSL Limited, Bayer AG
View The Full Adenosine Deaminase-Severe Combined Immunodeficiency Market Report:
Adenosine Deaminase-Severe Combined Immunodeficiency Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2025. The regions covered in the adenosine deaminase-severe combined immunodeficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
